Astera Cancer Care began its in-state expansion with the recent addition of three oncology practices, in Jersey City, Marlton and Rutherford. Astera Cancer Care now has over 60 cancer care providers at 18 care delivery sites across New Jersey and Pennsylvania, with several additional care delivery sites under development.
The acquisitions expand the physician-owned multispecialty community oncology practice’s ability to deliver high-quality, coordinated and patient-centered cancer care throughout New Jersey.
“By bringing these exceptional practices into Astera Cancer Care, we are able to deliver to patients the highest-quality cancer care, including a portfolio of cutting-edge clinical trials, close to their homes no matter where they live in New Jersey,” said Dr. Edward Licitra, chairman and CEO, Astera Cancer Care, and a member of OneOncology’s board of managers. “These new physician partners will allow Astera to expand their unique value-based care delivery platform and provide New Jersey residents with greater access to high-quality, affordable health care and the most innovative therapies, which are comparable to those found at academic medical centers. Innovative care models in the community offer the highest value in health care delivery to patients, payers and self-funded employers.”
The three practices, Hudson Hematology Oncology, Lindenberg Cancer & Hematology Center and Dr. Guiseppe Condemi’s Rutherford-based practice, will each serve as a regional hub in Astera Cancer Care’s expansion efforts. Astera Cancer Care, with the assistance of OneOncology’s physician recruitment team, has already recruited several well-trained medical oncologists to join these three practices and to expand into additional areas throughout New Jersey and beyond.
“From advanced diagnostics and therapies to a robust clinical trials program to one of the nation’s leading value-based care programs, Astera Cancer Care is driving the future of cancer care in New Jersey,” said Dr. Jeff Patton, CEO, OneOncology. “We are excited to help them build new cancer centers, add physicians, expand patient-centric value-based care and grow their services along the continuum of care throughout the Garden State.”
The center offers a diverse portfolio of innovative treatments, including chemotherapy, biologic therapy, immunotherapy and a robust clinical trial platform for cancer therapy with one of the nation’s only community-based clinical trial programs in CAR-T cell therapy.
